As we continue our review and discussion of early new product developments at ESMO this year, it’s time to turn our attention to some IO based agents, either along or in combination with other approaches.

Is the situation a bright and breezy one or full of gloomy clouds with little or no silver lining to speak of?

Yesterday’s review of early targeted agents was a surprisingly popular one, so let’s see how the immunotherapy based approaches do…

BSB subscribers can read more on our latest update and commentary from the ESMO conference – you can log-in or click to access our latest analysis.

This content is restricted to subscribers

Posted by